Tag
This review synthesizes emerging evidence demonstrating robust effectiveness of RSV vaccination in reducing hospitalization, death, and severe outcomes among elderly nursing home residents during the vaccine’s inaugural season.
A pooled analysis from 22 countries demonstrates that rotavirus vaccination is highly effective in preventing rotavirus-positive acute gastroenteritis deaths in children under five, underscoring the vaccine’s critical role in reducing
This review synthesizes recent evidence on the effectiveness of 2024-2025 COVID-19 vaccines in adults, highlighting moderate protection against symptomatic illness, hospitalization, and critical outcomes, with emphasis on waning immunity an
This review synthesizes current evidence on the effectiveness of adjuvanted RSVPreF3 vaccination in reducing RSV-related hospitalizations among older US adults, highlighting substantial protection across high-risk subgroups.
A secondary analysis of the DANFLU-2 trial confirms that high-dose influenza vaccine significantly reduces cardiorespiratory hospitalizations in older adults with diabetes, with potentially enhanced benefits for those with longer disease du
A comprehensive meta-analysis of 121.8 million individuals confirms that RSV vaccines are approximately 75% effective against hospitalization and severe disease in older adults, despite low global uptake and a rare risk of Guillain-Barré sy
A multicenter study reveals that 2024-2025 COVID-19 vaccines offer 40% protection against hospitalization and 79% against critical illness or death, maintaining efficacy against emerging JN.1 descendants like KP.3.1.1 and XEC.
This review analyzes the long-term effectiveness of RSV vaccination among US Veterans, revealing significant protection against severe outcomes that wanes over two seasons, particularly in immunocompromised populations.
The DANFLU-2 trial found that while high-dose influenza vaccines significantly reduced influenza-specific hospitalizations in older adults, they did not reach statistical significance for the combined primary endpoint of influenza or pneumo
In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung d
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing at
RSV vaccines demonstrate substantial effectiveness and acceptable safety profiles in adults aged ≥60, with diminished effectiveness in immunocompromised subgroups and a low, statistically significant increased risk of Guillain-Barré syndrom
This article reviews two types of flu vaccines for children—live attenuated and inactivated—over 20 years, demonstrating both provide meaningful protection and highlighting improvements that have enhanced their effectiveness.
A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populat
A large multicenter study demonstrates that a single dose of RSV vaccine reduces hospitalization risk by 58% among adults aged 60+, with lower effectiveness in immunocompromised and cardiovascular patients.
A UK-wide multicentre study shows maternal bivalent RSV prefusion F vaccination reduces infant hospitalisation for RSV-associated ALRI by up to 72%, confirming real-world effectiveness matching clinical trials.
Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulner
A prospective study shows split-virion vaccines offer significantly higher protection against influenza than subunit vaccines in adults 50 and older, highlighting the importance of vaccine selection.
